PriceTargets.com logo

GeneDx - WGS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $134.78
  • Forecasted Upside: -0.85%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$135.94 As of 12/17/2025 05:00 PM ET
▼ -5.78 (-4.08%)

This chart shows the closing price for WGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GeneDx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WGS

Analyst Price Target is $134.78
▼ -0.85% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for GeneDx in the last 3 months. The average price target is $134.78, with a high forecast of $200.00 and a low forecast of $80.00. The average price target represents a -0.85% upside from the last price of $135.94.

This chart shows the closing price for WGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in GeneDx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/17/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/17/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/15/2025Wells Fargo & CompanySet TargetEqual Weight ➝ Equal Weight$140.00 ➝ $155.00
12/12/2025BTIG ResearchBoost TargetBuy ➝ Buy$165.00 ➝ $200.00
11/4/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$95.00 ➝ $140.00
10/29/2025Canaccord Genuity GroupSet TargetBuy ➝ Buy$155.00 ➝ $160.00
10/29/2025GuggenheimReiterated RatingBuy ➝ Buy$115.00 ➝ $170.00
10/29/2025BTIG ResearchBoost TargetBuy ➝ Buy$140.00 ➝ $165.00
10/22/2025BTIG ResearchBoost TargetBuy ➝ Buy$125.00 ➝ $140.00
10/20/2025Canaccord Genuity GroupSet TargetBuy$155.00
10/20/2025Canaccord Genuity GroupInitiated CoverageBuy$155.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
10/2/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/11/2025Piper SandlerBoost TargetOverweight ➝ Overweight$120.00 ➝ $140.00
8/4/2025Piper SandlerSet TargetOverweight ➝ Overweight$110.00 ➝ $120.00
7/30/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$78.00 ➝ $95.00
7/9/2025Piper SandlerInitiated CoverageOverweight$110.00
6/30/2025GuggenheimReiterated RatingBuy ➝ Buy$88.00 ➝ $115.00
5/15/2025GuggenheimInitiated CoverageBuy$88.00
5/9/2025Jefferies Financial GroupUpgradeHold ➝ Buy$80.00
5/1/2025TD SecuritiesLower TargetBuy ➝ Buy$135.00 ➝ $110.00
5/1/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$105.00 ➝ $78.00
2/19/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$70.00 ➝ $80.00
1/7/2025TD CowenBoost TargetBuy ➝ Buy$75.00 ➝ $118.00
10/30/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$54.00 ➝ $70.00
10/30/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$34.00 ➝ $75.00
10/30/2024Craig HallumBoost TargetBuy ➝ Buy$70.00 ➝ $95.00
10/24/2024Craig HallumBoost TargetBuy ➝ Buy$46.00 ➝ $70.00
10/16/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$32.00 ➝ $54.00
8/27/2024Wells Fargo & CompanyInitiated CoverageEqual Weight$34.00
7/31/2024TD CowenBoost TargetBuy ➝ Buy$46.00 ➝ $50.00
7/31/2024BTIG ResearchBoost TargetBuy ➝ Buy$35.00 ➝ $45.00
7/31/2024Craig HallumBoost TargetBuy ➝ Buy$43.00 ➝ $46.00
7/31/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$28.00 ➝ $32.00
7/17/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$12.50 ➝ $28.00
7/10/2024Craig HallumInitiated CoverageBuy$43.00
6/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$19.00 ➝ $35.00
6/3/2024Jefferies Financial GroupInitiated CoverageHold$21.00
4/30/2024TD CowenBoost TargetBuy ➝ Buy$14.00 ➝ $24.00
4/30/2024BTIG ResearchBoost TargetBuy ➝ Buy$15.00 ➝ $19.00
4/22/2024BTIG ResearchBoost TargetBuy ➝ Buy$11.00 ➝ $15.00
4/15/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$11.00
12/7/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$99.00 ➝ $33.00
11/17/2022BTIG ResearchLower Target$66.00
11/15/2022CowenLower TargetOutperform$165.00 ➝ $99.00
11/15/2022CowenLower TargetOutperform$165.00 ➝ $99.00
8/18/2022BTIG ResearchLower TargetBuy$165.00 ➝ $99.00
8/16/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$132.00 ➝ $66.00
6/2/2022The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$115.50
5/16/2022Compass PointLower TargetNA$165.00
5/16/2022CowenLower Target$429.00 ➝ $165.00
1/21/2022BTIG ResearchReiterated RatingBuy$264.00
11/19/2021The Goldman Sachs GroupInitiated CoverageBuy$396.00
10/8/2021BTIG ResearchInitiated CoverageBuy$396.00
9/30/2021CowenInitiated CoverageOutperform$429.00
9/24/2021Jefferies Financial GroupInitiated CoverageBuy$429.00
(Data available from 12/18/2020 forward)

News Sentiment Rating

1.28 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 45 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2025
  • 26 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2025
  • 23 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
Mentions as of
7/20/2025
  • 31 very positive mentions
  • 40 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
8/19/2025
  • 39 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/18/2025
  • 15 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2025
  • 29 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2025
  • 34 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2025

Current Sentiment

  • 34 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

GeneDx logo
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $135.94
Low: $133.90
High: $144.59

50 Day Range

MA: $140.55
Low: $116.91
High: $167.51

52 Week Range

Now: $135.94
Low: $55.17
High: $170.87

Volume

452,974 shs

Average Volume

451,314 shs

Market Capitalization

$3.93 billion

P/E Ratio

1,510.44

Dividend Yield

N/A

Beta

1.99

Frequently Asked Questions

What sell-side analysts currently cover shares of GeneDx?

The following equities research analysts have issued reports on GeneDx in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Guggenheim, Jefferies Financial Group Inc., Piper Sandler, TD Cowen, TD Securities, The Goldman Sachs Group, Inc., Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for WGS.

What is the current price target for GeneDx?

0 Wall Street analysts have set twelve-month price targets for GeneDx in the last year. Their average twelve-month price target is $134.78, suggesting a possible downside of 0.9%. BTIG Research has the highest price target set, predicting WGS will reach $200.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $80.00 for GeneDx in the next year.
View the latest price targets for WGS.

What is the current consensus analyst rating for GeneDx?

GeneDx currently has 1 sell rating, 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for WGS.

What other companies compete with GeneDx?

Other companies that are similar to GeneDx include Guardant Health, Hims & Hers Health, Caris Life Sciences, BrightSpring Health Services and RadNet. Learn More about companies similar to GeneDx.

How do I contact GeneDx's investor relations team?

GeneDx's physical mailing address is 333 Ludlow Street North Tower 8th Floor, Stamford CT, 06902. The company's listed phone number is 800-298-6470 and its investor relations email address is [email protected]. The official website for GeneDx is sema4.com. Learn More about contacing GeneDx investor relations.